ECE2022 Oral Communications Oral Communications 4: Pituitary and Neuroendocrinology 1 (6 abstracts)
Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey
Susan Webb 1,2 , Dermot O’Toole 3 , Pamela Kunz 4 , Aude Houchard 5 , Sandra Boiziau 5 , Antonio Ribeiro-Oliveira 6 & Ally Prebtani 7
1Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Endocrinology Department, Spain; 2Universitat Autònoma de Barcelona (UAB), Research Center for Pituitary Diseases, Hospital Sant Pau, IIB-Sant Pau, and Dept Medicine, Spain; 3St. Vincent’s University Hospital, Neuro Endocrine Tumours-ENETS Centre of Excellence, Dublin, Ireland; 4Yale School of Medicine, Medicine (Oncology), New Haven, CT, United States; 5Ipsen, Boulogne Billancourt, France; 6Ipsen, Boston, MA, United States; 7McMaster University, Faculty of Health Sciences, Ontario, Canada
Introduction: Long-acting (LA) somatostatin analog (SSA) therapy is a common first-line medical treatment for acromegaly and NETs. There are limited real-world data on patients’ injection experience with the latest LA SSA devices/formulations.
Aims: To compare the injection experience of patients with acromegaly or NETs who were receiving treatment with LAN prefilled syringe vs OCT syringe.
Methods: A 2021 e-survey of adults with acromegaly or NETs from Canada, USA, UK and Ireland who had received ≥3 months’ treatment with LAN or OCT (planned sample size, 304 [min 76/cohort]; 50:50 ratio [+/- 10%]). The primary endpoint was the proportion of patients with pain at injection site lasting >2 days after last injection. Secondary endpoints included interference with daily life due to injection-site pain and occurrence of technical injection problems. Benefits of independent injection (by self or partner) were assessed among patients receiving LAN, excluding patients in the USA, where LAN independent injection is not in the approved labelling.
Results: There were 304 respondents (acromegaly, n=85; NETs, n=219; LAN, n=168; OCT, n=136; 69.2% female; mean age 59.6 years). Fewer patients had injection-site pain lasting >2 days after last dose with LAN (6.0%) vs OCT (22.8%); the odds of pain lasting >2 days were significantly lower for LAN vs OCT, adjusted for disease group and occurrence of injection-site reaction (OR 0.13 [95% CI 0.06–0.30]; P<0.0001). Secondary endpoints are summarized in the table. In the LAN group (excluding USA), 40.7% (n=11) of patients with acromegaly and 38.7% (n=29) with NETs received their last treatment via independent injection and indicated they chose this for flexibility (80.0%), time saved (70.0%) and it was easy to do (60.0%).
| Endpoint | LAN | OCT |
| Interference with daily life due to injection-site pain, %a | n=78 | n=80 |
| 59.0 | 40.0 | |
| Not at all | 37.2 | 52.5 |
| A little bit | 3.8 | 7.5 |
| Quite a bit | 0 | 0 |
| Very much | ||
| Frequency of technical problems with injection, %b | ||
| Never | n=155 | n=126 |
| 76.8 | 42.9 | |
| Rarely | 17.4 | 39.7 |
| About half the time | 1.9 | 11.1 |
| Most of the time | 1.3 | 5.6 |
| Don’t know/remember | 2.6 | 0.8 |
| aPatients with pain at last injectionbPatients with >6 months’ experience with current SSA | ||
Conclusions: In this e-survey, LAN was associated with advantages relative to OCT beyond improvements in the occurrence of technical problems, especially regarding duration of pain at injection site and its interference with daily life. A substantial proportion of LAN patients had received independent injection, demonstrating the value of this treatment option.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more